Blueprint Medicines announces new data from ARROW trial of BLU-667
Blueprint Medicines announced updated data from the ongoing registration-enabling ARROW trial of BLU-667 in patients with RET-altered cancers. The data presented at the American Society of Clinical Oncology 2019 Annual Meeting show durable clinical activity in patients with RET-altered non-small cell lung cancer, medullary thyroid cancer and other cancers. Designed by Blueprint Medicines, BLU-667 is a potent and highly selective oral inhibitor of RET fusions and mutations, including predicted resistance mutations. The new results support Blueprint Medicines' plans to submit an initial New Drug Application to the U.S. FDA for BLU-667 for the treatment of patients with RET-fusion NSCLC previously treated with platinum-based chemotherapy in the first quarter of 2020, and an NDA to the FDA for the treatment of patients with RET-mutant MTC previously treated with an approved multi-kinase inhibitor in the first half of 2020.